Nothing Special   »   [go: up one dir, main page]

UY28524A1 - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
UY28524A1
UY28524A1 UY28524A UY28524A UY28524A1 UY 28524 A1 UY28524 A1 UY 28524A1 UY 28524 A UY28524 A UY 28524A UY 28524 A UY28524 A UY 28524A UY 28524 A1 UY28524 A1 UY 28524A1
Authority
UY
Uruguay
Prior art keywords
antagonists
oxitocine
derivatives replaced
triazol derivatives
inhibitors
Prior art date
Application number
UY28524A
Other languages
English (en)
Inventor
Alan Daniel Brown
David Ellis
Christopher Ronald Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY28524A1 publication Critical patent/UY28524A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una clase de 1,2,4-triazoles sustituídos de fórmula (I) con actividad como antagonistas de oxitocina, a sus usos, a procesos para su preparación y a composiciones que contienen dichos inhibidores. Estos inhibidores tienen utilidad en una diversidad de áreas terapéuticas incluyendo la disfunción sexual, particularmente la eyaculación precoz (P.E.).
UY28524A 2003-09-22 2004-09-20 Derivados de triazol sustituidos como antagonistas de oxitocina UY28524A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
UY28524A1 true UY28524A1 (es) 2005-04-29

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28524A UY28524A1 (es) 2003-09-22 2004-09-20 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (12)

Country Link
EP (1) EP1673355A1 (es)
JP (1) JP2007505888A (es)
AR (1) AR045791A1 (es)
BR (1) BRPI0414663A (es)
CA (1) CA2539297C (es)
MX (1) MXPA06003158A (es)
NL (1) NL1027084C2 (es)
PA (1) PA8613001A1 (es)
PE (1) PE20050950A1 (es)
TW (1) TW200526606A (es)
UY (1) UY28524A1 (es)
WO (1) WO2005028452A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
KR101374553B1 (ko) * 2004-11-18 2014-03-17 신타 파마슈티칼스 코프. Hsp90 활성을 조절하는 트리아졸 화합물
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US7618972B2 (en) * 2005-03-21 2009-11-17 Pfizer Inc Substituted triazole derivatives as oxytocin antagonists
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
KR20130105914A (ko) 2008-09-22 2013-09-26 카이맨 케미칼 컴파니 인코포레이티드 H-pgds 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 d2 매개된 질병의 치료를 위한 그의 용도
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
KR20190094187A (ko) 2016-12-21 2019-08-12 지앙수 헨그루이 메디슨 컴퍼니 리미티드 축합 고리기 아자시클로부틸 트리아졸 유도체, 이의 제조 방법 및 의약에서의 이의 용도
US20210040073A1 (en) 2016-12-28 2021-02-11 Jiangsu Hengrui Medicine Co., Ltd. Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine
TW202016091A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種otr抑制劑的可藥用鹽、晶型及製備方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
HUP0302415A2 (hu) * 2000-05-19 2003-11-28 Merck Patent Gmbh Triazolszármazékokat tartalmazó gyógyszerkészítmények és új triazolszármazékok
EP1273580B1 (en) * 2001-07-05 2005-06-15 Pfizer Products Inc. Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents
SI1458381T1 (sl) * 2001-12-20 2006-04-30 Applied Research Systems Triazoli kot oksitocinski antagonisti

Also Published As

Publication number Publication date
WO2005028452A1 (en) 2005-03-31
PA8613001A1 (es) 2005-08-04
AR045791A1 (es) 2005-11-16
MXPA06003158A (es) 2006-06-05
NL1027084A1 (nl) 2005-03-24
BRPI0414663A (pt) 2006-11-21
WO2005028452A9 (en) 2005-07-21
PE20050950A1 (es) 2005-11-11
CA2539297A1 (en) 2005-03-31
CA2539297C (en) 2010-07-20
TW200526606A (en) 2005-08-16
NL1027084C2 (nl) 2006-01-24
JP2007505888A (ja) 2007-03-15
EP1673355A1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
UY28524A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY27807A1 (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP045476A (es) Tiazolidinonas, su preparación y su uso como medicamentos
SV2003000925A (es) Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ATE437872T1 (de) Proteinkinaseinhibitoren
CL2011001360A1 (es) Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro.
UY30748A1 (es) Compuesto0s novedosos
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
WO2006100588A8 (en) Substituted triazole derivatives as oxytocin antagonists
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
WO2005082866A3 (en) Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
ECSP066931A (es) Nuevos imidazoles
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
PT1497292E (pt) Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150604